Building patient-focused companies around transformative technologies.

Hibiscus BioVentures provides the Technology, Capital and People necessary to build transformative biotechnology companies.

Our Mission

Committed to significantly moving patient care forward by supporting development of commercially viable therapeutics and diagnostics. Providing all the resources necessary in-house to identify major unmet medical needs and drive impactful solutions for patients.

 

Hibiscus Biotechnology Logo

Venture studio focused on building companies from the ground up around innovative technologies.

Hibiscus Capital Management Logo

Patient-focused venture capital arm investing in transformative biotechnology companies.

Our Latest News

Hibiscus BioVentures

AsclepiX Therapeutics, Inc. Appoints Robert J. Dempsey as Chief Executive Officer and President

| All, Asclepix Therapeutics | No Comments
Pharmaceutical Industry Veteran Further Strengthens the Executive Team BALTIMORE, MD, March 17, 2021 – AsclepiX Therapeutics, Inc., a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular…
Asclepix Therapetuics Eye

AsclepiX Therapeutics partners with Notal Vision on Home OCT remote monitoring in DME and AMD clinical trials

| All, Asclepix Therapeutics | No Comments
The technology could set new standards for data enrichment and patient-centric conduct of clinical trials February 23, 2021 08:00 ET | Source: Notal Vision Manassas, VA, Feb. 23, 2021 (GLOBE…

Barer & Son Capital and Hibiscus Capital Management Announce Successful Initial Public Offering of Portfolio Company NexImmune

| All, NexImmune | No Comments
  NexImmune Raises Gross Proceeds of $126.5M in Upsized IPO after Full Exercise of Underwriters' Option to Purchase Additional Shares ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ -- Barer & Son…